IMmunotherapy: Prospective Assessment of Cannabis Treatment in Cancer
Recruiting now
Conditions studied: Cancer
In brief
The purpose of this research is to assess how patients with cancer being treated with Immune Checkpoint Inhibitors (ICI) manage symptoms related to cancer and/or its treatment. Patients use a variety of ways to manage symptoms including traditional and alternative treatments including cannabis, acupuncture, etc. This research will have an important impact on our knowledge of cancer symptom management, and ultimately improve patient care and safety. Participants will complete online surveys and 7 days of ecological momentary assessments at 0, 1, 2, 4, 6, 9 and 12 month to compare the cannabis users and non cannabis users symptoms.
Key facts
- Study ID
- NCT06206941
- Run by
- State University of New York at Buffalo
- People needed
- 450
- Starts
- 2025-01-02
- Expected to finish
- 2027-12-31
- Last updated by the study team
- 2025-10-31
Who can join
Age: 21 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- adult age of 21 years or older
- cancer diagnosis and planning or using immunotherapy treatment,
- pain and spend less than 50% in bed or chair
- fluent in english language
You may not qualify if…
- use synthetic cannabis or only use Cannabidiol (CBD)
- non users but used in the past 3 months
- prior immunotherapy, Patients receiving immunosuppressants or organ transplant recipients.
- Patients within 6 months of Hospice care.
- Pain that limits movement to more than 50% of their day in bed or chair
Where it is running
- Thomas Jefferson University — Philadelphia, Pennsylvania, United States (enrolling)
- Oregon Health and Science University — Portland, Oregon, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.